Neurology

Back to articles

Pharmacists need a better understanding of generic drug approvals

November 20, 2018
  • Advising on this article:
  • Jack J. Chen

KEY POINT

An assessment of community pharmacists’ understanding of FDA therapeutic equivalence standards and bioequivalence criteria showed that many pharmacists need additional education on these topics, according to survey results published in Research in Social and Administrative Pharmacy.

SOURCES

Euen BJ, et al. Community pharmacists' understanding and perceptions of FDA therapeutic equivalence standards. Res Social Adm Pharm. 2018;[Epub ahead of print].

FDA. FDA Drug Topics: Building Confidence in Generic Narrow Therapeutic Index (NTI) Drugs – September 18, 2018. Accessed: October 28, 2018.

 

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.